Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.44 |
| ▸ | DRD3 | P35462 | 8/20 | 0.44 |
| ▸ | ABCC9 | O60706 | 3/20 | 0.44 |
| ▸ | ABCC8 | Q09428 | 3/20 | 0.44 |
| ▸ | KCNJ11 | Q14654 | 3/20 | 0.44 |
| ▸ | KCNJ8 | Q15842 | 3/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13674316 | 0.81 | DDB1 (0.37) | DDB1CRBNUSP30CYP19A1 | |
| SCHEMBL1264106 | 0.76 | NFKB1 (0.38) | DDB1CRBNNFKB1NPSR1 | |
| SCHEMBL27617540 | 0.73 | DRD2 (0.44) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL29683775 | 0.73 | DRD2 (0.50) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL8688588 | 0.72 | DRD2 (0.51) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL4674179 | 0.72 | DRD2 (0.56) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL21452585 | 0.72 | DRD2 (0.49) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL27219407 | 0.71 | DRD2 (0.48) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL18767643 | 0.71 | DRD2 (0.41) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL4875328 | 0.70 | DRD2 (0.67) | DRD2DRD3ABCC9ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453501-B1 | N- ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORP (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7348328-B2 | MCH antagonists for the treatment of obesity | SCHERING CORPORATION (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1453501-A1 | N- ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040122017-A1 | MCH antagonists for the treatment of obesity | SCHERING CORPORATION | 2004-06-24 | — | — | US | disclosed |
| WO-2003047568-A1 | N-ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122017-A1 | MCH antagonists for the treatment of obesity | MCHR1, MCHR2, MC4R | DRD2 257/4885DRD3 321/4885ABCC9 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.